Intercept Pharmaceuticals’ reported that their experimental medicine to treat nonalcoholic steatohepatitis (NASH) achieved its primary goal in a Phase 3 trial, giving it a shot at becoming the first drug to treat the condition. NASH is a chronic disease in which fat accumulates in the liver; patients in the advanced stages of NASH present with cirrhosis and may require a liver transplant in order to survive. (STAT)